Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Telix Pharmaceuticals Ltd. ( (AU:TLX) ) is now available.
Telix Pharmaceuticals Limited has announced a change in the address of its registry office in Sydney, which is now located at Liberty Place, Level 41, 161 Castlereagh St, Sydney NSW 2000. This relocation is part of the company’s ongoing operational adjustments, reflecting its commitment to maintaining efficient administrative processes and potentially impacting its stakeholder communications.
More about Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Headquartered in Melbourne, Australia, Telix operates internationally in the United States, Brazil, Canada, Europe, and Japan, with a portfolio targeting significant unmet medical needs in oncology and rare diseases.
YTD Price Performance: 14.35%
Average Trading Volume: 5,321
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.57B
See more data about TLX stock on TipRanks’ Stock Analysis page.